BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND
Cannasoft" or the "Company") announced today plans to enter the
multibillion-dollar Sextech Industry as its Zigi Carmel Initiatives
& Investments subsidiary filed a U.S. Provisional Patent
Application for an additional smart female treatment device for
external use. The new artificial intelligence (AI) based device
will be capable of treating certain phenomena in female sexual
organs. Sextech is a $30 billion industry today, however, according
to an analysis report, the industry should grow to $52.7 billion by
2026 with a huge assist from online sales.i The company plans to
develop the new AI based device as well as its EZ-G device.
The device utilizes an artificial intelligence
and machine learning algorithms to control the operational
parameters of the device based on physiological parameters of the
user. The device performs operations including stimulating the
sexual organs based on user preferences as well as real time data
indicative of satisfaction level of the user monitored by sensors.
The patent application covers AI that stores user preference data
and uses that data to learn general preferences and current
operation preferences. This AI component will collect data on the
response to various operation parameters and adjust the user
preference data accordingly to provide learning capabilities and
fine tune its operation as it gets to know its user.
BYND Cannasoft's believes this AI based device
also has tremendous potential to capture significant market share
as a sex toy, since the technology behind this patent application
has the potential to improve the interaction between human and
machine. The AI has the capability to collect data on the user’s
response to vary stimulation patterns, determine lubricant
dispensing rate, and determine sexual climax of the user by using
artificial intelligence and machine learning based on data
collected and the previous user’s response. This learned AI is
designed to provide the user with a natural experience in a
controlled manner based on user preferences and real time data. The
device also includes a communication component that uses the data
and information it has gathered from its sensors to create custom
programs and upload the data to the cloud.
Yftah Ben Yaackov, CEO and Director of BYND
Cannasoft said, "Our new AI based device comes at a pivotal time as
most companies are changing their focus to connect with their
customers in more automated and personalized ways. Real-time
technologies and generative AI are paving the way for how consumers
think and influencing the items they purchase. BYND Cannasoft
intends to pursue the final registration of its patents and
establish a marketing and sales system for our new AI device and
the EZ-G device based on B2B and B2C sales."
BYND previously announced it had filed US
Provisional Patent Application number 63/297,009 on January 6, 2022
and PCT application number PCT/IL2023/050016 on January 5, 2023
covering the monitoring and controlling aspects of its EZ-G device.
The EZ-G device is a therapeutic device combined with proprietary
AI-based software that regulates the flow of low-concentration oils
into the soft tissues of the female reproductive system. This
process could prove beneficial to pain associated with trauma,
complications from surgery or other medical procedures,
vulvovaginal atrophy due to a drop of estrogen following menopause,
vulvar vestibulitis related to a highly localized burning or
cutting type of pain, and cervical cancer. The EZ-G device can
utilize naturally derived oils, such as CBD and hempseed, as well
as commercially manufactured varieties.
About BYND Cannasoft Enterprises
Inc.
BYND Cannasoft Enterprises is an Israeli-based
integrated software and cannabis company. BYND Cannasoft owns and
markets "Benefit CRM," a proprietary customer relationship
management (CRM) software product enabling small and medium‐sized
businesses to optimize their day‐to‐day business activities such as
sales management, personnel management, marketing, call center
activities, and asset management. Building on our 20 years of
experience in CRM software, BYND Cannasoft is developing an
innovative new CRM platform to serve the needs of the medical
cannabis industry by making it a more organized, accessible, and
price-transparent market. The Cannabis CRM System will include a
Job Management (BENEFIT) and a module system (CANNASOFT) for
managing farms and greenhouses with varied crops. BYND Cannasoft
owns the patent-pending intellectual property for the EZ-G device.
This therapeutic device uses proprietary software to regulate the
flow of low concentrations of CBD oil, hemp seed oil, and other
natural oils into the soft tissues of the female reproductive
system to potentially treat a wide variety of women's health
issues. The EZ-G device includes technological advancements as a
sex toy with a more realistic experience and the prototype utilizes
sensors to determine what enhances the users' pleasure. The user
can control the device through a Bluetooth app installed on a
smartphone or other portable device. The data will be transmitted
and received from the device to and from the secure cloud using
artificial intelligence (AI). The data is combined with other
antonymic user preferences to improve its operation by increasing
sexual satisfaction.
For Further Information please
refer to information available on the Company’s website:
www.cannasoft-crm.com, the CSE’s website:
www.thecse.com/en/listings/life-sciences/bynd-cannasoft-enterprises-inc
and on SEDAR: www.sedar.com.
Gabi Kabazo
Chief Financial Officer
Tel: (604) 833-6820
e‐mail: ir@cannasoft-crm.com
For Media and Investor Relations, please
contact:
David L. Kugelman
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
dk@atlcp.com
Skype: kugsusa
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 involving risks and uncertainties, which may
cause results to differ materially from the statements made. We
intend such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. When used
in this document, the words "may," "would," "could," "will,"
"intend," "plan," "anticipate," "believe," "estimate," "expect,"
"potential," "continue," "strategy," "future," "project," "target,"
and similar expressions are intended to identify forward-looking
statements, though not all forward looking statements use these
words or expressions. All statements contained in this press
release other than statements of historical fact, including,
without limitation, statements regarding our additional smart
female treatment device , our Cannabis CRM platform, our expanded
EZ-G patent application, our market growth, and our objectives for
future operations, are forward looking statements. Additional
regulatory standards may be required, including FDA approval or any
other approval for the purpose of manufacturing, marketing, and
selling the devices under therapeutic indications. There is no
certainty that the aforementioned approvals will be received, and
all the information in this release is forward-looking. Such
statements reflect the company's current views with respect to
future events and are subject to such risks and uncertainties. Many
factors could cause actual results to differ materially from the
statements made, including unanticipated regulatory requests and
delays, final patents approval, and those factors discussed in
filings made by the company with the Canadian securities regulatory
authorities, including (without limitation) in the company's
management's discussion and analysis for the nine month period
ended September 30, 2022 and annual information form dated October
8, 2022, which are available under the company's profile
at www.sedar.com, and in filings made with the U.S. Securities
and Exchange Commission. Should one or more of these factors occur,
or should assumptions underlying the forward-looking statements
prove incorrect, actual results may vary materially from those
described herein as intended, planned, anticipated, or expected. We
do not intend and do not assume any obligation to update these
forward‐looking statements, except as required by law. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change. Shareholders are cautioned not to put undue reliance on
such forward‐looking statements.
____________________________
i
https://www.forbes.com/sites/bernardmarr/2020/11/30/future-of-intimacy-sex-bots-virtual-reality-and-smart-sex-toys/?sh=43e7996338fa
Femto Technologies (NASDAQ:BCAN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Femto Technologies (NASDAQ:BCAN)
Historical Stock Chart
From Dec 2023 to Dec 2024